Clinical prognostic significance of cancer stem cell markers in patients with papillary thyroid carcinoma

Introduction

Thyroid carcinoma is the most common endocrine malignancy, and its incidence has increased globally in recent decades (1). In Korea, thyroid carcinoma diagnoses have also risen rapidly, accounting for 14.2% of all cancer cases in 2014 (2). Papillary thyroid carcinoma (PTC) accounts for the majority of the newly diagnosed cases (3). PTC has a very good prognosis; however, even after appropriate treatment, 10–20% of patients experience recurrence, with 2–5% developing distant metastases between several years and several decades following treatment (4). Since a number of patients who experience recurrence eventually succumb to cancer, the establishment of prognostic factors for recurrence is an important part of PTC treatment.

The cancer stem cell (CSC) theory attracted interest when it was first introduced in the 1990s as a novel target for potential curative treatment for cancer (5). However, the discovery that CSCs have plasticity and may exhibit a reversible phenotype with non-CSCs, along with the observation that CSCs are not a rare population in tumors, makes this theory complicated and difficult to adopt in clinical practice. Despite these limitations, the CSC theory still has clinical relevance, as these cells are believed to be able to sustain or generate new tumors. In our previous study in collaboration with the MD Anderson Cancer Center, CD44+/CD24− were proposed as phenotypic markers for CSCs in PTC (6). However, since PTC is insufficiently aggressive to generate new cancers in animal models, the tumorigenic potential of PTC CSCs could not be proven. The present study aimed to define the prognostic significance of CD44 and CD24 expression using immunohistochemistry (IHC) on samples from patients with PTC, in order to identify the clinical significance of these CSC markers.

Materials and methods

Patients and tissue samples

Between July 2003 and December 2012, PTC samples were collected from 500 patients with PTC (tumor size, >1 cm) that underwent successful surgical resection at Seoul National University Bundang Hospital; these samples were analyzed in this retrospective study. Patients who received prior treatment or could not commit to 6 months of follow-up care were excluded. This study was approved by the Institutional Review Board at Seoul National University Bundang Hospital (approval no. B-1507/306-310). Previously prepared paraffin blocks of surgical specimens were examined by two pathologists. Paraffin blocks of primary tumor tissues were not available for 46 of the 500 patients; therefore, samples from 454 patients were selected for the generation of tissue microarrays (TMAs). The clinicopathological characteristics of the patients are summarized in Table I.

Table I. Clinicopathological characteristics of the patients (n=454).

Table I.

Clinicopathological characteristics of the patients (n=454).

Variable	Median (range)	N (%)
Sex
Male		107 (23.6)
Female		347 (76.4)
Age at surgery, years	48.0 (10–87)
<60		92 (20.3)
≥60		362 (79.7)
cN1b		94 (20.7)
pN1
≤5		351 (77.3)
>5		103 (22.7)
T stage
T1		101 (22.2)
T2		14 (3.1)
T3		332 (73.1)
T4		7 (1.5)
Pathological tumor size, cm	1.4 (1.0–7.0)
≤2		332 (73.1)
>2		122 (26.9)
Multifocality		204 (44.9)
Extrathyroidal extension
No		117 (25.8)
Microscopic		235 (51.8)
Macroscopic		102 (22.5)
Surgery
Lobectomy/total		21/433
thyroidectomy		(4.6/95.4)
CND/CND + LND		281/96
		(61.9/21.1)
First relapse
Thyroid remnant or bed		3 (0.7)
Central compartment LN		5 (1.1)
Lateral compartment LN		27 (5.9)
Distant site		8 (1.8)
Time to first relapse, months	22 (2–101)
Follow-up time, months	70 (6–141)
Death
Cancer		0 (0)
Other causes		2 (0.4)

[i] CND, central compartment neck dissection; LN, lymph node; LND, lateral compartment neck dissection; T stage, pathologic Tumor-Node-Metastasis T stage (American Joint Committee on Cancer, 7th edition) (21).

TMA

Following the review of 454 tumor tissues, representative core tissue sections (diameter, 2 mm) were extracted from the paraffin blocks and arranged in new TMA blocks using a trephine apparatus (Superbiochips Laboratories), according to the manufacturer's protocol. The TMA blocks were sectioned into 4-µm slices for IHC.

IHC staining

This study evaluated the expression of two proteins in tumor tissues: CD44 and CD24. The following antibodies were used: Rabbit monoclonal anti-CD44 (1:600; Boster Biological Technology Co., Ltd.; cat. no. PA1021-2) and mouse monoclonal anti-CD24 (1:50; Abcam; cat. no. MA5-11833). Using the Discovery XT automated IHC instrument (Ventana Medical Systems, Inc.), the sections were stained using the following procedures. Firstly, detection was performed using a Ventana Chromo Map kit (Ventana Medical Systems, Inc.). Sections were deparaffinized using an EZ Prep solution included in the Chromo Map kit. CC1 standard (Tris, borate and EDTA buffer; pH 8.4) was used for antigen retrieval (at 95°C for 44 min). Treatment with Inhibitor D (3% H2O2) for 4 min at 37°C was used to block endogenous peroxidase. Sections were then incubated with primary antibodies for 32 min at 37°C and with an OmniMap anti-mouse secondary antibody (Ventana Medical Systems, Inc.; cat. no. 760-4310) for 20 min at 37°C. Sections were incubated in 3,3′-diaminobenzidine + H2O2 substrate for 8 min at 37°C, followed by hematoxylin and eosin reagent counterstain for 2 min at 37°C. Reaction buffer (Tris buffer; pH 7.6) was used as a washing solution. Slides were evaluated on a Zeiss Axioskop light microscope (Carl Zeiss) equipped with Zeiss Plan-Neofluar objective lenses (×40, ×200).

IHC grades

Immunostaining was evaluated by two independent pathologists, who were blind to the experimental design, and the IHC scores were determined semi-quantitatively based on staining intensity and proportion. IHC expression was graded according to the following staining intensity criteria: 0, no staining; 1, weak staining; 2, moderate staining; and 3, strong staining.

Tonsils from children undergoing tonsillectomy were used as a positive control (Fig. 1) (7). Tissues that scored ≤1 were considered negative (−), whereas >1 was marked as positive (+) for statistical analysis (Fig. S1)

Figure 1. Immunohistochemical staining pattern of papillary thyroid carcinoma. (A) CD44 positive control from a human tonsil. (B) CD44+. (C) CD44−. (D) CD24 positive control from a human tonsil. (E) CD24+. (F) CD24−.

Statistical analysis

SPSS software (version 19.0; IBM Corp.) was used for statistical analysis. Pearson's χ2 test was used to analyze the relationship between protein expression and clinicopathological data. Recurrence-free survival (RFS) was determined based on the positive and negative expressions of proteins using Kaplan-Meier survival analysis and univariate log-rank test. In addition, a multivariate Cox regression test was performed to identify factors affecting RFS. P<0.05 was considered to indicate a statistically significant difference.

Results

Patient clinicopathological characteristics

A total of 454 patients with PTC were included in this study. Relevant demographic, clinical and pathological data, as well as management and survival data of the patients were retrieved and summarized in Table I. A higher number of female compared with male patients with PTC [female, 347 (76.4%) vs. male, 107 (23.6%)] were enrolled. Their age ranged between 10 and 87 (median, 48.0) years. A total of 92 patients (20.3%) were <60 years old, whereas the remaining 362 patients (79.7%) were ≥60 years old. Of the 454 patients, 94 (20.7%) were suspected to have lateral lymph node metastasis at the time of diagnosis (cN1b). Histopathologically, 351 patients (77.3%) exhibited ≤5 lymph node metastases, whereas 103 patients (22.7%) exhibited >5 lymph node metastases. According to the Tumor-Node-Metastasis (TNM) staging system (8), 101 patients (22.2%) were classed as T stage 1, 14 (3.1%) as stage 2, 332 (73.1%) as stage 3 and seven as stage 4 (1.5%). There were 332 patients (73.1%) with primary tumor diameters ≤2 cm in size and 122 patients (26.9%) with tumor diameters >2 cm; 204 (44.9%) patients exhibited multifocality. A total of 117 patients (25.8%) did not exhibit an extrathyroidal extension, 235 (51.8%) exhibited a microscopic extrathyroidal extension and 102 (22.5%) exhibited a gross extrathyroidal extension. Total thyroidectomy was performed in the majority of patients (95.4%). Central lymph node dissection was performed in 377 patients (83.0%), of which 96 patients (21.1%) also underwent lateral lymph node dissection. The median follow-up period was 70 months and two patients were lost to the follow-up due to unrelated causes. PTC recurred in 39 (8.6%) patients, with certain patients exhibiting multiple instances of recurrence in different locations. The median time to first recurrence was 22 months. Recurrence sites were as follows: Three cases in the thyroid remnant or bed, five cases in the central lymph node area, 27 cases in the lateral lymph node area and eight cases of distant metastases.

Association of IHC results with clinical data in patients with PTC

The majority of clinicopathological characteristics did not demonstrate a statistically significant association with single CSC markers; however, age (P=0.001), extrathyroidal extension (P=0.039) and cancer recurrence (P<0.001) exhibited a significant association with CD24 expression (Table II).

Table II. Association between CD44 and CD24 and the clinical data of patients with papillary thyroid carcinoma.

Table II.

Association between CD44 and CD24 and the clinical data of patients with papillary thyroid carcinoma.

Variable	CD44−	CD44+	χ2	P-value	CD24−	CD24+	χ2	Ρ-value	Others	CD44+/CD24−	χ2	P-value
Age, years
<60	8	82	0.590	0.574	50	44	11.889	0.001a	45	44	9.079	0.004a
≥60	41	308			125	244			235	112
Sex
Male	13	91	0.246	0.597	40	69	0.073	0.822	68	36	0.081	0.815
Female	36	299			135	219			212	120
Tumor size, cm
≤2	34	287	0.391	0.608	132	206	0.840	0.389	203	116	0.176	0.675
>2	15	103			43	82			77	40
cN1b
No	41	306	0.714	0.461	136	233	0.684	0.407	225	120	0.715	0.393
Yes	8	84			39	55			55	36
pN1
≤5	42	297	2.182	0.140	128	221	2.141	0.143	224	113	3.266	0.071
>5	7	92			46	57			56	43
Multifocality
No	29	211	0.454	0.545	91	165	1.233	0.289	161	78	2.275	0.134
Yes	20	179			84	123			119	78
Extrathyroidal extension
No + Micro	40	302	0.445	0.587	127	233	4.368	0.039a	227	113	4.351	0.041a
Macro	9	88			48	55			53	44
Recurrence
No	48	352	3.191	0.105	148	274	15.061	<0.001a	268	129	20.858	<0.001a
Yes	1	38			27	14			12	27

a P<0.05, χ² test.

Associations of the combined status of CD44+ and CD24− with clinicopathological data in patients with PTC were also determined. A statistically significant association was identified between the recurrence of cancer for all combinations of CSC markers. Particularly, the combination of CD44+/CD24− exhibited a significant association with age and gross extrathyroidal extensions (Table II).

RFS according to clinical data and IHC

RFS curves according to clinical data and IHC results are presented in Fig. 2. As determined using Kaplan-Meier survival analysis and univariate log-rank test, sex (P=0.008), age (P=0.002), cN1b (P<0.001), pN1 >5 (P<0.001), tumor size >2 cm (P<0.001), extrathyroidal extension (P=0.001) and CD24− (P<0.001) were prognostic factors for RFS. The CSC marker combination CD44+/CD24− also exhibited statistical significance in the log-rank test. In multivariate analysis, CD44+/CD24− was identified as an independent prognostic factor for PTC with a hazard ratio of 4.207 (Table III).

Figure 2. Kaplan-Meier plots of RFS according to clinical data and immunohistochemistry. RFS plots based on (A) sex; (B) age at surgery; (C) cN1b stage; (D) pN1 stage; (E) tumor size; (F) multifocality; (G) extrathyroidal extension; (H) CD44 status; (I) CD24 status; and (J) CD44+/CD24− status. RFS, recurrence-free survival.

Table III. Multivariate analysis of recurrence-free survival.

Table III.

Multivariate analysis of recurrence-free survival.

Variable	Hazard ratio	95% CI	P-value
Age (>60)	1.911	0.937–3.895	0.075
Sex (male)	2.262	1.174–4.359	0.015a
Size (>2 cm)	2.576	1.200–5.527	0.015a
cN1b	2.606	0.909–7.474	0.075
pN1 (>5)	2.426	0.858–6.861	0.095
Gross ETE	1.259	0.573–2.769	0.566
CD44+/CD24−	4.207	2.088–8.479	<0.001a

a P<0.05, Cox regression analysis. 95% CI, 95% confidence interval; ETE, extrathyroidal extension.

Discussion

Cancer prognosis and treatment efficacy are ultimately determined by survival of the patient, and the criteria for staging are based on factors related to survival. However, in the case of a differentiated thyroid carcinoma, cancer progression is very slow (9); therefore, even in the case of recurrence, a cure is possible following further operations and treatment with radioactive iodine (10). If thyroid carcinoma is not cured, a long and considerable period of palliative care may follow. Therefore, in the case of differentiated thyroid carcinoma, the prognosis may not be determined based on survival alone; instead, analyzing RFS may be a more reasonable approach (11). In the present study, no patients succumbed to PTC during the 70-month median follow-up period, and the recurrence rate was 8.6%, similar to previous prognostic studies (3,12).

Thyroid CSCs can be distinguished by the expression of specific biomarkers, the ability to produce thyrospheres in vitro and the ability to induce tumors in vivo (13). Zito et al (14) first attempted to isolate CSCs in 2008 by analyzing the expression of CD133 through flow cytometry in thyroid cancer cell lines. Subsequently, Friedman et al (15) demonstrated that the transplantation of CD133+ cells into immunodeficient NOD/SCID mice is sufficient to induce tumor growth in vivo. Our previous study on CSCs focused on CD44 and CD24, which are CSC markers for certain cancers, including breast and colon cancer (16). Using specific cancer cell lines (TPC-1 and its derivatives), higher numbers of CD44+/CD24− cells have been identified in more aggressive cell lines (positivity rates: 86% in highly tumorigenic TPC-1 mouse cells; >73% in moderately tumorigenic TPC-1SC2 cells; and >21% in parental, poorly tumorigenic TPC-1 cells) (4). Subsequently, 4–70% of dispersed cells from thyroid cancers have been determined to be CD44+/CD24−. These cells form spheres; however, CD44+/CD24−, but not CD44+/CD24+ cells from these spheres are spherogenic. The cells derived from thyrospheres (≥1×104) form tumors following orthotopic injection in an immunodeficient mice model (6). However, the impact of these markers on clinical outcome could not be assessed in the previous study. Therefore, the present study used PTC surgical specimens in TMAs to conduct standardized IHC experiments.

To the best of our knowledge, the present study is the first to analyze the association between CD44 and CD24 expression status and the clinical prognosis of PTC. The results of the present study demonstrated that the expression of CD44 or CD24, as determined by IHC, was not associated with commonly known prognostic factors in patients with PTC, with the exception of the presence of gross extrathyroidal extension. Recently, the American Joint Committee on Cancer (AJCC) 8th edition for thyroid cancers downstaged a large number of patients by raising the age at diagnosis cut off from 45 to 55 years (8). This change was confirmed by the identification of a good prognosis in patients aged between 45 and 55 years in an international multi-institutional validation study of 9,484 patients (17). Similarly, in the present study, a difference in IHC outcome and prognostic analysis at index age 45 years was not observed (data not shown). However, when the index age was raised to 60 years, differences in CD44+/CD24− expression status and prognosis were detected.

A significant association between RFS and CD24 expression was identified using Kaplan-Meier analysis. CD44 exhibited an association with RFS, which was not statistically significant. In addition, CSC marker combination analysis, including CD44+/CD24−, exhibited a statistically significant association with RFS. These results were consistent with the findings of Bi et al (18), which revealed that the IHC results for CD44+/CD133+ in medullary thyroid carcinoma are correlated with survival; in addition, CD44+/CD24− is associated with prognosis in patients with other types of cancer, such as breast (19).

At present, surgery, radiotherapy, chemotherapy and hormonal therapy are used to treat thyroid cancer; however, these treatments often exhibit limited efficacy. Conventional therapies target highly proliferating cells that form the majority of the tumor mass, but are ineffective against slowly proliferating or quiescent CSCs, which are responsible for drug resistance, metastasis and recurrence (20). However, the clinical importance of the presence of CSC markers, evaluated by IHC, remains uncertain. Due to their plasticity, whether the cells positive for these markers are actually CSCs is unknown. Even if IHC evaluation precisely reflects cancer stemness, the overall interpretation of such data is still challenging (19). However, it is beneficial for such efforts to be continued, since the ability to identify, isolate and study thyroid CSCs has a number of implications with potential novel therapeutic consequences.

In conclusion, the expression status of CD44+ and CD24− in tissue samples was associated with RFS of patients with PTC. Particularly, the combination of CD44+ and CD24− exhibited a significant association with RFS and gross extrathyroidal extension. Therefore, measuring CD44+/CD24− expression in order to evaluate the prognosis associated with RFS may be of use in PTC.

Supplementary Material

Supporting Data

Acknowledgements

All data in the present study were reconstructed based on a master's thesis prepared by Dr Yoon-Jong Ryu under supervision of Professor Soon-Hyun Ahn (Department of Otorhinolaryngology Head and Neck Surgery, Seoul National University College of Medicine).

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

YJR and SHA conceived and designed the study. YJR acquired and analyzed the data. JYC and KL contributed to the interpretation of the data. YJR and SHA wrote and revised the paper. JYC and KL provided administrative, technical, or material support. SHA supervised the study.

Ethics approval and consent to participate

The present study was approved by the Institutional Review Board at Seoul National University Bundang Hospital (approval no. B-1507/306-310). Written informed consent was waived due to the retrospective nature of the study.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References